Head-To-Head Comparison: Oncology Pharma (OTCMKTS:ONPH) vs. BigBear.ai (NYSE:BBAI)

Oncology Pharma (OTCMKTS:ONPH) and BigBear.ai (NYSE:BBAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Volatility & Risk

Oncology Pharma has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, BigBear.ai has a beta of 3.39, meaning that its stock price is 239% more volatile than the S&P 500.

Profitability

This table compares Oncology Pharma and BigBear.ai’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Pharma	N/A	N/A	N/A
BigBear.ai	-55.14%	-4,639.70%	-43.21%

Valuation & Earnings

This table compares Oncology Pharma and BigBear.ai’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Pharma	N/A	N/A	N/A	N/A	N/A
BigBear.ai	$161.62 million	1.60	-$121.67 million	($0.67)	-2.48

Oncology Pharma has higher earnings, but lower revenue than BigBear.ai.

Analyst Recommendations

This is a summary of current ratings and price targets for Oncology Pharma and BigBear.ai, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Pharma	0	0	0	0	N/A
BigBear.ai	0	0	1	0	3.00

BigBear.ai has a consensus price target of $4.00, indicating a potential upside of 140.96%. Given BigBear.ai’s higher probable upside, analysts clearly believe BigBear.ai is more favorable than Oncology Pharma.

Insider and Institutional Ownership

1.5% of BigBear.ai shares are owned by institutional investors. 18.0% of Oncology Pharma shares are owned by insiders. Comparatively, 2.0% of BigBear.ai shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BigBear.ai beats Oncology Pharma on 5 of the 9 factors compared between the two stocks.

About Oncology Pharma

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

About BigBear.ai

BigBear.ai Holdings, Inc. provides artificial intelligence and machine learning for decision support. The company operates through two segments, Cyber & Engineering and Analytics. The Cyber & Engineering segment offers high-end technology and management consulting services. It focuses in the areas of cloud engineering and enterprise IT, cybersecurity, computer network operations and wireless, systems engineering, and strategy and program planning. The Analytics segment provides high-end technology and consulting services. This segment focuses on the areas of big data computing and analytical solutions, including predictive and prescriptive analytics solutions. Its solutions assist customers in aggregating, interpreting, and synthesizing data to enable real-time decision-making capabilities. The company's customers include federal defense and intelligence agencies, manufacturers, third party logistics providers, retailers, healthcare, and life sciences organizations. The company is headquartered in Columbia, Maryland.